· Venture Capital Tracker Editorial · investment-strategies
Encoded Therapeutics Raises $275M Series F to Take Its Dravet Gene Therapy Through Pivotal Development
GV and an unnamed healthcare fund co-led Encoded Therapeutics' $275 million Series F, financing pivotal ETX101 studies, internal GMP scale-up, and a 2027 IND target for ETX301.
Encoded Therapeutics closed a $275 million Series F on September 9, 2026. GV and an unnamed healthcare fund co-led, with ARCH Venture Partners, Braidwell, Farallon, Illumina Ventures, Invus, Janus Henderson, Matrix Capital, Nolan Capital, RTW Investments, SoftBank Vision Fund 2, and Venrock participating.
the financing is a late-stage clinical and manufacturing bet. It is intended to carry lead program ETX101 through pivotal development while scaling internal GMP capacity rather than outsourcing the entire production path.
Key facts
| Field | Detail |
|---|---|
| Company | Encoded Therapeutics |
| Financing | $275M Series F, closed |
| Co-leads | GV; one unnamed healthcare fund |
| Lead program | ETX101 for SCN1A+ Dravet syndrome |
| Development | Pivotal study in infants and young children; expansion study through age 18 |
| Pipeline | ETX301 targeting a 2027 IND submission for post-amputation neuroma pain |
| Manufacturing | Commercial scale-up of internal GMP capabilities |
What the round must prove
Encoded describes ETX101 as a one-time precision genetic medicine. The company cited interim Phase 1/2 POLARIS data showing seizure-frequency reductions and developmental gains, but the financing thesis now shifts from early signal to pivotal evidence, registration readiness, and reproducible manufacturing.
The internal GMP expansion may create more control over quality and timelines. It also increases fixed-cost and execution exposure before approval.
Why an anonymous co-lead matters
The company disclosed GV but not the second healthcare fund. That anonymity should be preserved: it is not evidence that any other participant co-led. The broad syndicate supplies biotechnology, crossover, and growth capital, but Encoded did not disclose valuation, ownership, or round structure.
What remains undisclosed
- Valuation and primary/secondary mix
- The identity of the second co-lead
- Trial enrollment, pivotal timelines, and regulatory milestones beyond the stated programs
- Expected cost and capacity of the GMP expansion
Takeaway
The $275 million is large because Encoded is financing three linked risks at once: a pivotal study, commercial manufacturing preparation, and a follow-on neurology pipeline. The next valuation-relevant evidence will be clinical durability and the ability to manufacture consistently—not the size of this syndicate.
Day index: September 11–12 investment news.
Source
Follow Venture Capital Tracker in Google
Add VCT as a preferred source to make our venture-capital coverage easier to find in Google Search.
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.
